{
  "docId": "019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "docSlug": "05d98084f9bd31c78a17b84718191aae",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 39,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "Slide compares two different product portfolios using stacked bar charts over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-a5cb-72a4-ac7d-0f26e10cd805/15",
  "deckHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "deckJsonHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805.json",
  "deckAnchorHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Brilinta revenue growth by quarter",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c074ae28-3529-4d3a-ae53-8d84acbfaf0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.32,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Farxiga revenue growth by quarter",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d40deab3-fa94-418d-b518-f1237e0e486a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "1. Sodium-glucose co-transporter 2 (inhibitor). 2. Type-2 diabetes. 3. IQVIA market research. 4. Volume-based procurement.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed1f4c6f-3497-4ad0-99d5-157fc82eb5cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.68,
        "y": 0.33
      },
      "kind": "list",
      "text": "Brilinta +2%: COVID-19 impact in all regions and China VBP price change",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b69d3ea-5d1d-4d8a-a025-0060d3085537",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.37,
        "y": 0.33
      },
      "kind": "list",
      "text": "Farxiga +30% US +6% Strong market growth offset by some price Ex US (71% of total) Europe +35% Strong volume growth; SGLT2 leadership in several markets EMs +55% Leading SGLT2; benefit from NRDL",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54e3045a-7bf6-4f81-a553-866219e0e4a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Farxiga inflection point; strong progress",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eba0342-4bef-4b66-9ab2-5ad5232bb0a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "BioPharmaceuticals: New CVRM",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e72af9eb-b6ee-45a6-a5c9-45e369720148",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 13,
      "beatId": "f46a0338-6851-4c4f-8928-0fddd4ceb387",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides satisfaction with strong growth and pipeline progress",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}